NCM
INAB icon

Nantahala Capital Management’s IN8bio INAB Stock Holding History

Nantahala Capital Management’s Portfolio INAB Stock Details INAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,960
Closed -$359K – 125
2022
Q2 		$359K Sell
4,960
-6,798
-58% -$575K 0.02% 107
2022
Q1 		$1.23M Sell
11,758
-681
-5% -$76.2K 0.05% 99
2021
Q4 		$1.64M Sell
12,439
-61
-0.5% -$12K 0.06% 112
2021
Q3 		$2.57M Buy
+12,500
New +$3.11M 0.08% 98

Other funds holding INAB

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
SIG
Stonegate Investment Group Birmingham, Alabama $4.31B AUM 18.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PM
Precept Management Dallas, Texas $126M AUM 36.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Nantahala Capital Management's INAB Position: Q3 2022 in Review

Nantahala Capital Management sold out of IN8bio (INAB) in Q3 2022, closing a stake of 4,960 shares — an estimated $359K sold.

Nantahala Capital Management first reported a position in INAB in Q3 2021 and held it in 4 quarters. The position peaked at $2.57M in Q3 2021. 17 funds tracked by Wall St. Rank hold INAB as of Q3 2022.

  • Nantahala Capital Management reported no remaining IN8bio position as of Q3 2022 after selling out during the quarter.
  • Nantahala Capital Management sold 4,960 IN8bio shares in Q3 2022, an estimated $359K.
  • Nantahala Capital Management first reported a position in IN8bio in Q3 2021 and held it in 4 quarters.
  • Nantahala Capital Management's IN8bio position peaked at $2.57M in Q3 2021.
  • 17 funds tracked by Wall St. Rank held IN8bio as of Q3 2022.

Based on Nantahala Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.